Abstract Tracks

The Ghana AIDS Commission, the organisers of NHARCON 2018 request for works that introduce novel ideas and/or concepts, new research findings and advances in the field.
Submit an abstract by following the guidelines provided below:

The conference will have three main tracks namely:

Track A:        Social and Behavioural Science;
Track B:         Epidemiology, Basic and Clinical Science
Track C:        Interventions and Best Practices

Each Scientific Track is divided into a number of track categories. All persons submitting abstracts are requested to choose a Scientific Track and a Track Category that best describes their subject of abstract. Accepted abstracts will be published under the general headings of these scientific tracks.

Track A: Social and Behavioural Science
A1. Stigma and discrimination and impact on HIV and TB
A2. Sex, sexuality, gender relationships, HIV and TB responses
A3. Policies, programmes and HIV and TB response.
A4. Communication, mass media and popular education.
A5. Socio-cultural determinants of HIV.
A6. Structural determinants of HIV.
A7. Human rights, law and ethics.

A8. Sex Work: Behavioural, Social and Cultural Issues and Contexts

A9. Living with HIV and AIDS
A10. Ethics and Human Rights
A11. Adolescents, young people and relationships
A12. Fertility, family planning, reproductive health services and HIV
A13. Policy development, implementation and evaluation
A14. Violence, conflict and Humanitarian disasters and HIV
A15. Prisons, closed settings  HIV and TB
A16. Family-centered approach to HIV care and support

poverty, wealth, income inequalities and HIV

  A17. Illicit drug use policies, harm reduction and socio-cultural factors
Track B: Epidemiology, Basic and Clinical Science
B1. HIV evolution, viral diversity and bioinformatics
B2. HIV co-infections (TB, Hepatitis A,B,C) and

emerging pathogens

B3. Interaction of micronutrients, nutrition and

HIV infection

B4. Clinical Course of HIV infection and disease
B5. HIV and Non Communicable Diseases (NCD)
B6. Immunology of HIV & Vaccine Development
B7. Antiretroviral Therapy
B8. HIV and AIDS Surveillance, Monitoring and Evaluation
B9. HIV and AIDS Prevention Programmes
B10. Diagnostic and Monitoring Tools
B11. Co-Morbidities and Complications (including those related to ART)
B12. Other Strategies and Therapies (non-ART)
B13. Specific Issues Related to HIV Infection in Women
B14. Specific Issues Related to HIV Infection in Infants, Children and Adolescents
B15. Specific Issues Related to HIV Infection and Treatment in Key Populations
A18. Illicit drug use policies, harm reduction and socio-cultural factors
Track C Interventions and Best Practices
C1. Antiretroviral therapy
C1.1 First line therapy (when to start, what to start with, durability)
C1.2 Treatment failure: drug resistance, second line therapy and salvage therapy
C1.3 Adherence and retention
C1.4 Antiretroviral therapy in children
C1.5 HIV management in adolescents
C1.6 Antiretroviral therapy in pregnant women
C1.7 Antiretroviral therapy in elder populations
C1.8 Management of HIV infection in Key Populations
C1.9 Antiretroviral therapy to prevent HIV-Transmission– Diversified prevention tools: PeP PrEP TAsP Microbicides
C1.10 Treat all
C2. Palliative care and nutrition
C2.1 Pain management and end of life care
C2.2 Clinical nutritional care in HIV infection
C2.3 Home and community based care and support
C2.4 Other Strategies and Therapies (traditional medicine, spiritual care)
C3. Policies, Programs, guidelines and HIV response
C3.1 Country adaptation of global HIV diagnosis and treatment guidelines
C3.2 Diagnosis and monitoring tools
C3.3 Harm reduction policies and politics
C3.4 HIV policies and the workplace
C3.5 HIV policies and educational institutions
C4. Innovation and best practices
C4.1 Interventions at scale (community, district, provincial, regional, country levels) to increase uptake of and retention in HIV services
C4.2 Partnership involving donors, NGOs and government
C4.3 Effects of public-private partnerships, including workplace programmes and policies
C4.4 Innovating HIV response with new technologies
C4.5 Working with community-led organizations, including key populations, faith-based groups, traditional healer organizations, and with community leaders
C4.6 Differentiated Models of Care and Service Delivery
C4.7 Non-ARV Based Interventions to Combat HIV/AIDS
C4.8 mHealth and the Global HIV Response
C5. Integration of HIV Services with Other Programmes – best practices
C5.1 Integration of HIV services with other health programmes
C5.2 Integration of HIV and HCV services
C5.3 Integration of HIV services with other development programmes
C5.4 Integration of prevention interventions with care/treatment
C6. Diagnostics – best practices
C6.1 Scale up of paediatric diagnosis
C6.2 Scale up of point-of-care technologies
C6.3 Scale up of viral load monitoring
C6.4 Optimal split between laboratory-based and point-of-care devices
C7. Monitoring and Evaluation – best practices
C7.1 Monitoring and evaluation of prevention
C7.1 Monitoring and evaluation of testing
C7.2 Monitoring and evaluation of treatment and care
C7.3 Monitoring and evaluation of HIV cascade
C7.4 Monitoring and evaluation of health systems
C8. Implementation Science
C8.1 Operational challenges in implementing HIV services
C8.2 Adherence to HIV treatment
C8.3 Uptake of HIV services
C8.4 Retention in HIV services
C8.5 Linkage between HIV services
C8.6 Differentiated models of care
C8.7 Combination interventions that span prevention / screening / treatment